Cancer and Leukemia Group B. A national (US) clinical research group sponsored by the NCI, with its central office headquartered at the University of Chicago and its statistical centre located at Duke University.
Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.
Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX)[+ or -]cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results.
Just how far chemotherapy has come in the past 20 years was best illustrated by a comparison of outcomes between ER-negative participants in CALGB 8541 who were on the standard adjuvant chemotherapy regimen of 20 years ago--low-dose cyclophosphamide, doxorubicin, and fluorouracil--and patients in CALGB 9741 on a much more contemporary regimen of concurrent high-dose doxorubicin and cyclophosphamide followed by paclitaxel with dosing every 2 weeks.
More recently the CALGB 9781 trial, which was closed early due to poor accrual, reported a long-term survival advantage with the use of chemoradiotherapy followed by surgery in patients with mainly adenocarcinoma of the oesophagus based on the analysis of its 56 enrolled patients .
ORLANDO -- Hopes that the addition of bevacizumab to gemcitabine would improve survival in patients with advanced pancreatic cancer have been dashed by the disappointing results of CALGB 80303, a phase III randomized trial presented at a symposium on gastrointestinal cancers sponsored by the American Society of Clinical Oncology.